Targeted killing of TNFR2-expressing tumor cells and T_regs by TNFR2 antagonistic antibodies in advanced Sezary syndrome.

ABSTRACT: Sézary syndrome (SS) is a rare form of cutaneous T-cell lymphoma often refractory to treatment. SS is defined as adenopathy, erythroderma with high numbers of atypical T cells. This offers an opportunity for new interventions and perhaps antibody-based therapeutic by virtue of its high expression of the TNFR2 oncogene on the tumor cells and on T-regulatory cells (T_regs). Potent human-directed TNFR2 antagonistic antibodies have been created that preferentially target the TNFR2 oncogene and tumor-infiltrating TNFR2⁺ T_regs. Here we test the therapeutic potential of TNFR2 antagonists on freshly isolated lymphocytes from patients with Stage IVA SS and from healthy controls. SS patients were on a variety of end-stage multi-drug therapies. Baseline burden T_re

SUBMITTER: Torrey H 

PROVIDER: S-EPMC6756055 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature